Flare‑up of cytokines in rheumatoid arthritis and their role in triggering depression: Shared common function and their possible applications in treatment (Review)
- Authors:
- Chunhai Zhang
-
Affiliations: Thyroid Surgery Department, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 1300332, P.R. China - Published online on: November 19, 2020 https://doi.org/10.3892/br.2020.1392
- Article Number: 16
-
Copyright: © Zhang . This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Brennan FM and McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 118:3537–3545. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ungethuem U, Haeupl T, Witt H, Koczan D, Krenn V, Huber H, von Helversen TM, Drungowski M, Seyfert C, Zacher J, et al: Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. Physiol Genomics. 42A:267–282. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Nixon R, Bansback N and Brennan A: The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford). 46:1140–1147. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van Herwaarden N and den Broeder AA: Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 5(CD010455)2019.PubMed/NCBI View Article : Google Scholar | |
|
Upchurch KS and Kay J: Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 51:vi28–vi36. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Quan LD, Thiele GM, Tian J and Wang D: The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat. 18:723–738. 2008.PubMed/NCBI View Article : Google Scholar | |
|
O'Dell JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 350:2591–2602. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Mori S: Management of rheumatoid arthritis patients with interstitial lung disease: Safety of biological antirheumatic drugs and assessment of pulmonary fibrosis. Clin Med Insights Circ Respir Pulm Med. 9 (Suppl 1):S41–S49. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW, Dijkmans BA and Allaart CF: The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 70:1039–1046. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Inui K and Koike T: Combination therapy with biologic agents in rheumatic diseases: Current and future prospects. Ther Adv Musculoskelet Dis. 8:192–202. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Bruce TO: Comorbid depression in rheumatoid arthritis: Pathophysiology and clinical implications. Curr Psychiatry Rep. 10:258–264. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Jacob L, Rockel T and Kostev K: Depression risk in patients with rheumatoid arthritis in the United Kingdom. Rheumatol Ther. 4:195–200. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Margaretten M, Julian L, Katz P and Yelin E: Depression in patients with rheumatoid arthritis: Description, causes and mechanisms. Int J Clin Rheumtol. 6:617–623. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Schiepers OJ, Wichers MC and Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 29:201–217. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Viatte S, Plant D and Raychaudhuri S: Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol. 9:141–153. 2013.PubMed/NCBI View Article : Google Scholar | |
|
McInnes IB and Schett G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7:429–442. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 423:356–361. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kinne RW, Stuhlmüller B and Burmester GR: Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther. 9(224)2007.PubMed/NCBI View Article : Google Scholar | |
|
Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E and Burmester GR: Macrophages in rheumatoid arthritis. Arthritis Res. 2:189–202. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T and Sakaguchi S: Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 114:582–588. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Schett G and Gravallese E: Bone erosion in rheumatoid arthritis: Mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 8:656–664. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Silveira KD, Coelho FM, Vieira AT, Barroso LC, Queiroz-Junior CM, Costa VV, Sousa LF, Oliveira ML, Bader M, Silva TA, et al: Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. Peptides. 46:53–63. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Ruscitti P, Cipriani P, Liakouli V, Carubbi F, Berardicurti O, Di Benedetto P, Ciccia F, Guggino G, Alvaro S, Triolo G and Giacomelli R: The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes. Rev Recent Clin Trials. 13:210–214. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zou Y, Zeng S, Huang M, Qiu Q, Xiao Y, Shi M, Zhan Z, Liang L, Yang X and Xu H: Inhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis. Br J Pharmacol. 174:893–908. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Buckley CD: Michael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints? Rheumatology (Oxford). 42:1433–1444. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kay J and Calabrese L: The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 43 (Suppl 3):iii2–iii9. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Arend WP, Palmer G and Gabay C: IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 223:20–38. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Nakae S, Saijo S, Horai R, Sudo K, Mori S and Iwakura Y: IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA. 100:5986–5990. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Abramson SB and Amin A: Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford). 41:972–980. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Jacques C, Gosset M, Berenbaum F and Gabay C: The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm. 74:371–403. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB and Tak PP: Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profiles. Am J Pathol. 172:940–950. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R, et al: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest. 108:1825–1832. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Lotz M: The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am. 25:269–282. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka T, Narazaki M and Kishimoto T: IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 6(a016295)2014.PubMed/NCBI View Article : Google Scholar | |
|
Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V and Ciliberto G: Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 187:461–468. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Kishimoto T: Interleukin-6: From basic science to medicine-40 years in immunology. Annu Rev Immunol. 23:1–21. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Narazaki M, Tanaka T and Kishimoto T: The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol. 13:535–551. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Marrelli A, Cipriani P, Liakouli V, Carubbi F, Perricone C, Perricone R and Giacomelli R: Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation? Autoimmun Rev. 10:595–598. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Johnson KE and Wilgus TA: Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle). 3:647–661. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Sokolove J and Lepus CM: Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis. 5:77–94. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H, Sanmarti R, et al: The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Semin Arthritis Rheum. 47:757–764. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol. 3:745–756. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Holnthoner W, Bonstingl C, Hromada C, Muehleder S, Zipperle J, Stojkovic S, Redl H, Wojta J, Schöchl H, Grillari J, et al: Endothelial cell-derived extracellular vesicles size-dependently exert procoagulant activity detected by thromboelastometry. Sci Rep. 7(3707)2017.PubMed/NCBI View Article : Google Scholar | |
|
Horiuchi T, Mitoma H, Harashima S, Tsukamoto H and Shimoda T: Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 49:1215–1228. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Chen X and Oppenheim JJ: Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 585:3611–3618. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Yamagishi S, Ohnishi M and Pawankar R: IL-1 and TNF-alpha-mediated regulation of IL-6, IL-8, and GM-CSF release from cultured nasal epithelial cells. Nihon Jibiinkoka Gakkai Kaiho. 103:829–835. 2000.PubMed/NCBI View Article : Google Scholar : (In Japanese). | |
|
Fiocco U, Sfriso P, Oliviero F, Lunardi F, Calabrese F, Scagliori E, Cozzi L, Di Maggio A, Nardacchione R, Molena B, et al: Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine. 80:165–170. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Bevaart L, Vervoordeldonk MJ and Tak PP: Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis? Arthritis Rheum. 62:2192–2205. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Monach PA, Benoist C and Mathis D: The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv Immunol. 82:217–248. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Hassan S, Milman U, Feld J, Eder L, Lavi I, Cohen S and Zisman D: Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: An analytical cohort study. Arthritis Res Ther. 18(261)2016.PubMed/NCBI View Article : Google Scholar | |
|
Ma X and Xu S: TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 1:177–184. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Bourne T, Fossati G and Nesbitt A: A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: Exploring a new mechanism of action. BioDrugs. 22:331–337. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Capria A, De Nardo D, Baffetti FR, Barbini U, Violo A, Tondo T and Fontana L: Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: The biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol. 23:255–262. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Tam LS, Kitas GD and Gonzalez-Gay MA: Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford). 53:1108–1119. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Moelants EA, Mortier A, Van Damme J and Proost P: Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol Cell Biol. 91:393–401. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lis K, Kuzawińska O and Balkowiec-Iskra E: Tumor necrosis factor inhibitors-state of knowledge. Arch Med Sci. 10:1175–1185. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Radner H and Aletaha D: Anti-TNF in rheumatoid arthritis: An overview. Wien Med Wochenschr. 165:3–9. 2015.PubMed/NCBI View Article : Google Scholar | |
|
van Schouwenburg PA, Rispens T and Wolbink GJ: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 9:164–172. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Dommasch E and Gelfand JM: Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther. 22:418–430. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Wolfe F and Michaud K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum. 56:2886–2895. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA and Ahmed J: Rheumatoid arthritis: A brief overview of the treatment. Med Princ Pract. 27:501–507. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Kalliolias GD and Liossis SN: The future of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs. 17:349–359. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ramírez J and Cañete JD: Anakinra for the treatment of rheumatoid arthritis: A safety evaluation. Expert Opin Drug Saf. 17:727–732. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Bresnihan B, Newmark R, Robbins S and Genant HK: Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol. 31:1103–1111. 2004.PubMed/NCBI | |
|
Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T and Yamamura T: Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology. 82:1302–1306. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Scott LJ: Tocilizumab: A review in rheumatoid arthritis. Drugs. 77:1865–1879. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T and Alten R: OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo controlled, randomised trial. Lancet. 371:987–997. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, et al: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54:2817–2829. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Yip RML and Yim CW: Role of interleukin-6 inhibitors in the management of rheumatoid arthritis. J Clin Rheumatol:. 2019, doi: 10.1097/RHU.0000000000001293 (Online ahead of print). | |
|
Park JY and Pillinger MH: Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 65 (Suppl 1):S4–S10. 2007.PubMed/NCBI | |
|
Conigliaro P, Triggianese P, De Martino E, Fonti GL, Chimenti MS, Sunzini F, Viola A, Canofari C and Perricone R: Challenges in the treatment of rheumatoid arthritis. Autoimmun Rev. 18:706–713. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S and Kola B: Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 35:1535–1563. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Gaffen SL: The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep. 11:365–370. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP and Verweij CL: Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis. 63:233–239. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Hodes GE, Ménard C and Russo SJ: Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress. 4:15–22. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Khandaker GM, Pearson RM, Zammit S, Lewis G and Jones PB: Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: A population-based longitudinal study. JAMA Psychiatry. 71:1121–1128. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Koo JW and Duman RS: Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs. 10:664–671. 2009.PubMed/NCBI | |
|
Raison CL, Capuron L and Miller AH: Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 27:24–31. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Steptoe A, Hamer M and Chida Y: The effects of acute psychological stress on circulating inflammatory factors in humans: A review and meta-analysis. Brain Behav Immun. 21:901–912. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Liu H, Luiten PG, Eisel UL, Dejongste MJ and Schoemaker RG: Depression after myocardial infarction: TNF-α-induced alterations of the blood-brain barrier and its putative therapeutic implications. Neurosci Biobehav Rev. 37:561–572. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K and Dickens C: Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res. 79:175–184. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kamel KM, Gad AM, Mansour SM, Safar MM and Fawzy HM: Venlafaxine alleviates complete Freund's adjuvant-induced arthritis in rats: Modulation of STAT-3/IL-17/RANKL axis. Life Sci. 226:68–76. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Song L, Quan X, Su L, Wang K, Wang H, Wu L, Chen C, Li S, Xiang W, Chen L and Zhou J: Inflammation and behavioral symptoms in preoperational glioma patients: Is depression, anxiety, and cognitive impairment related to markers of systemic inflammation? Brain Behav. 10(e01771)2020.PubMed/NCBI View Article : Google Scholar | |
|
Lu DY, Leung YM and Su LP: Interferon-α induces nitric oxide synthase expression and haem oxygenase-1 down-regulation in microglia: Implications of cellular mechanism of IFN-α-induced depression. Int J Neuropsychopharmacol. 16:433–444. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Carboni l, McCarthy DJ, Delafont B, Filosi M, Ivanchenko E, Ratti E, Learned SM, Alexander R and Domenici E: Biomarkers for response in major depression: Comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. Transl Psychiatry. 9(182)2019.PubMed/NCBI View Article : Google Scholar | |
|
Simen BB, Duman CH, Simen AA and Duman RS: TNFalpha signaling in depression and anxiety: Behavioral consequences of individual receptor targeting. Biol Psychiatry. 59:775–785. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Telfer JF and Brock JH: Proinflammatory cytokines increase iron uptake into human monocytes and synovial fibroblasts from patients with rheumatoid arthritis. Med Sci Monit. 10:BR91–BR95. 2004.PubMed/NCBI | |
|
Jenkins JK, Hardy KJ and McMurray RW: The pathogenesis of rheumatoid arthritis: A guide to therapy. Am J Med Sci. 323:171–180. 2002.PubMed/NCBI View Article : Google Scholar | |
|
De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, et al: Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 34:3493–3503. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kato H, Endres J and Fox DA: The roles of IFN-γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. Mod Rheumatol. 23:1140–1150. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes LA, Denys A, Feldmann M, Brennan FM and Foxwell BM: A novel mechanism for TNF-alpha regulation by p38 MAPK: Involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol. 173:6928–6937. 2004.PubMed/NCBI View Article : Google Scholar | |
|
De Cesaris P, Starace D, Riccioli A, Padula F, Filippini A and Ziparo E: Tumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathways. J Biol Chem. 273:7566–5671. 1998.PubMed/NCBI View Article : Google Scholar |
